Tech & Pharma
The Combined Heat and Power plant jointly developed by A*STAR and Hitachi achieves high efficiency with low operation costs.
Eisai grants Zeria the right to manufacture E3710, a proton pump inhibitor than can be used to treat gastric acid-related diseases.
Green Cross receives regulatory approval for its once-per-cycle dose neutropenia drug, Neulapeg®.
The CFDA approval of Mecobalamin marks Amerigen’s entry into the Chinese generics market.
Luye acquires the rights to Poziotinib, Hanmi’s pan-HER inhibitor for the treatment of cancer.
ZAI Lab has acquired the license for two pre-clinical drugs for chronic respiratory diseases.
PW Medtech expands its capabilities in medical devices with the acquisition of Beijing Tianxinfu Medical Appliance Co.
The partnership between Fosun and Taizhou Muncipal Hospital will add approximately 2,000 new hospital beds to serve the residents of Taizhou.
Celltrion predicts that it is one year away from approval for Remsima®, a biosimilar based on an originator drug from Janssen Biotech.
The National Cheng Kung University and Fujitsu will develop a cloud computing platform for big data analysis in agriculture and genomics research.